Loading…
Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma
Aim We investigated effects of direct‐acting antiviral (DAA)–induced sustained virological response (SVR) after liver resection in patients with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) for postoperative recurrence and survival. Methods Surgical outcomes in 18 patients with pos...
Saved in:
| Published in: | Hepatology research 2021-11, Vol.51 (11), p.1102-1114 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3 |
| container_end_page | 1114 |
| container_issue | 11 |
| container_start_page | 1102 |
| container_title | Hepatology research |
| container_volume | 51 |
| creator | Tanaka, Shogo Shinkawa, Hiroji Tamori, Akihiro Takemura, Shigekazu Uchida‐Kobayashi, Sawako Amano, Ryosuke Kimura, Kenjiro Ohira, Go Nishio, Kohei Tauchi, Jun Kinoshita, Masahiko Kawada, Norifumi Kubo, Shoji |
| description | Aim
We investigated effects of direct‐acting antiviral (DAA)–induced sustained virological response (SVR) after liver resection in patients with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) for postoperative recurrence and survival.
Methods
Surgical outcomes in 18 patients with postoperative DAA‐induced SVR (HCC‐DAA group) were compared with those in 23 patients with preoperative DAA‐induced SVR (DAA‐HCC group) and those in 10 patients who did not receive DAA therapy (control group). Patients who received DAA therapy >1 year after surgery and those with recurrence |
| doi_str_mv | 10.1111/hepr.13709 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2569384562</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2590169295</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3</originalsourceid><addsrcrecordid>eNp9kctKxDAUhosoOF42PkHAjQjVXNpOs5RBHWHAQRTclbQ91UinqSep4s4XEHxGn8Qz1pULs8m5fOfnhz-KDgQ_EfROH6HHE6GmXG9EE5FPZcxVcr9JtcqzOFNJth3teP_EuZhymUyij6XzwfWAJtgXYLVFqMLX-6epgu0emOlobNG0LCCYsIIuMNMEQNYSjgzBE29dx2zHetIgwLNXGx4ZWaE-WM9mjCQGT6oIrQlQjztXQdsOrUFWGaxs51ZmL9pqTOth__ffje4uzm9n83hxfXk1O1vElUpzHQuZcCO0KMtSc6iNqrWGUiilRKZ4rhKguqF1TSNp6CbNlRRNCkLqTJRqNzoadXt0zwP4UKysX9sxHbjBFzLNtMqTNJOEHv5Bn9yAHbkjSnORaalToo5HqkLnPUJT9GhXBt8KwYt1MsU6meInGYLFCL_aFt7-IYv5-fJmvPkGsaeVZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2590169295</pqid></control><display><type>article</type><title>Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tanaka, Shogo ; Shinkawa, Hiroji ; Tamori, Akihiro ; Takemura, Shigekazu ; Uchida‐Kobayashi, Sawako ; Amano, Ryosuke ; Kimura, Kenjiro ; Ohira, Go ; Nishio, Kohei ; Tauchi, Jun ; Kinoshita, Masahiko ; Kawada, Norifumi ; Kubo, Shoji</creator><creatorcontrib>Tanaka, Shogo ; Shinkawa, Hiroji ; Tamori, Akihiro ; Takemura, Shigekazu ; Uchida‐Kobayashi, Sawako ; Amano, Ryosuke ; Kimura, Kenjiro ; Ohira, Go ; Nishio, Kohei ; Tauchi, Jun ; Kinoshita, Masahiko ; Kawada, Norifumi ; Kubo, Shoji</creatorcontrib><description>Aim
We investigated effects of direct‐acting antiviral (DAA)–induced sustained virological response (SVR) after liver resection in patients with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) for postoperative recurrence and survival.
Methods
Surgical outcomes in 18 patients with postoperative DAA‐induced SVR (HCC‐DAA group) were compared with those in 23 patients with preoperative DAA‐induced SVR (DAA‐HCC group) and those in 10 patients who did not receive DAA therapy (control group). Patients who received DAA therapy >1 year after surgery and those with recurrence <1 year after surgery were excluded.
Results
Serum concentrations of aminotransferases improved 1 year after surgery in both the HCC‐DAA and DAA‐HCC groups. The number of HCC‐DAA patients with albumin‐bilirubin (ALBI) grade 1 increased from 11 to 15. The disease‐free survival rate did not differ between HCC‐DAA group (3 years, 60%) and the other two groups (DAA‐HCC group, 92% and control group, 60%). The 3‐year overall survival rates were better in the DAA‐HCC group (84%) and HCC‐DAA group (100%) than in the control group (46%; all ps < 0.05 according to Holm's test). Multivariable analysis revealed that tumor stage was an independent risk factor for postoperative recurrence, and ALBI grade at 1 year after surgery was predictive of postoperative survival, but DAA‐induced SVR was neither.
Conclusions
Although postoperative DAA‐induced SVR itself may not suppress postoperative recurrence, improvement in liver function as a result of DAA administration after surgery may prolong postoperative survival.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13709</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>antiviral agents ; Bilirubin ; carcinoma ; Hepatitis ; Hepatitis C ; hepatocellular ; Hepatocellular carcinoma ; immunotherapy ; Liver ; Liver cancer ; Patients ; Risk factors ; Surgery ; Surgical outcomes ; Survival ; Tumors</subject><ispartof>Hepatology research, 2021-11, Vol.51 (11), p.1102-1114</ispartof><rights>2021 Japan Society of Hepatology.</rights><rights>2021 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3</citedby><cites>FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Tanaka, Shogo</creatorcontrib><creatorcontrib>Shinkawa, Hiroji</creatorcontrib><creatorcontrib>Tamori, Akihiro</creatorcontrib><creatorcontrib>Takemura, Shigekazu</creatorcontrib><creatorcontrib>Uchida‐Kobayashi, Sawako</creatorcontrib><creatorcontrib>Amano, Ryosuke</creatorcontrib><creatorcontrib>Kimura, Kenjiro</creatorcontrib><creatorcontrib>Ohira, Go</creatorcontrib><creatorcontrib>Nishio, Kohei</creatorcontrib><creatorcontrib>Tauchi, Jun</creatorcontrib><creatorcontrib>Kinoshita, Masahiko</creatorcontrib><creatorcontrib>Kawada, Norifumi</creatorcontrib><creatorcontrib>Kubo, Shoji</creatorcontrib><title>Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma</title><title>Hepatology research</title><description>Aim
We investigated effects of direct‐acting antiviral (DAA)–induced sustained virological response (SVR) after liver resection in patients with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) for postoperative recurrence and survival.
Methods
Surgical outcomes in 18 patients with postoperative DAA‐induced SVR (HCC‐DAA group) were compared with those in 23 patients with preoperative DAA‐induced SVR (DAA‐HCC group) and those in 10 patients who did not receive DAA therapy (control group). Patients who received DAA therapy >1 year after surgery and those with recurrence <1 year after surgery were excluded.
Results
Serum concentrations of aminotransferases improved 1 year after surgery in both the HCC‐DAA and DAA‐HCC groups. The number of HCC‐DAA patients with albumin‐bilirubin (ALBI) grade 1 increased from 11 to 15. The disease‐free survival rate did not differ between HCC‐DAA group (3 years, 60%) and the other two groups (DAA‐HCC group, 92% and control group, 60%). The 3‐year overall survival rates were better in the DAA‐HCC group (84%) and HCC‐DAA group (100%) than in the control group (46%; all ps < 0.05 according to Holm's test). Multivariable analysis revealed that tumor stage was an independent risk factor for postoperative recurrence, and ALBI grade at 1 year after surgery was predictive of postoperative survival, but DAA‐induced SVR was neither.
Conclusions
Although postoperative DAA‐induced SVR itself may not suppress postoperative recurrence, improvement in liver function as a result of DAA administration after surgery may prolong postoperative survival.</description><subject>antiviral agents</subject><subject>Bilirubin</subject><subject>carcinoma</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>hepatocellular</subject><subject>Hepatocellular carcinoma</subject><subject>immunotherapy</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Survival</subject><subject>Tumors</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kctKxDAUhosoOF42PkHAjQjVXNpOs5RBHWHAQRTclbQ91UinqSep4s4XEHxGn8Qz1pULs8m5fOfnhz-KDgQ_EfROH6HHE6GmXG9EE5FPZcxVcr9JtcqzOFNJth3teP_EuZhymUyij6XzwfWAJtgXYLVFqMLX-6epgu0emOlobNG0LCCYsIIuMNMEQNYSjgzBE29dx2zHetIgwLNXGx4ZWaE-WM9mjCQGT6oIrQlQjztXQdsOrUFWGaxs51ZmL9pqTOth__ffje4uzm9n83hxfXk1O1vElUpzHQuZcCO0KMtSc6iNqrWGUiilRKZ4rhKguqF1TSNp6CbNlRRNCkLqTJRqNzoadXt0zwP4UKysX9sxHbjBFzLNtMqTNJOEHv5Bn9yAHbkjSnORaalToo5HqkLnPUJT9GhXBt8KwYt1MsU6meInGYLFCL_aFt7-IYv5-fJmvPkGsaeVZA</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Tanaka, Shogo</creator><creator>Shinkawa, Hiroji</creator><creator>Tamori, Akihiro</creator><creator>Takemura, Shigekazu</creator><creator>Uchida‐Kobayashi, Sawako</creator><creator>Amano, Ryosuke</creator><creator>Kimura, Kenjiro</creator><creator>Ohira, Go</creator><creator>Nishio, Kohei</creator><creator>Tauchi, Jun</creator><creator>Kinoshita, Masahiko</creator><creator>Kawada, Norifumi</creator><creator>Kubo, Shoji</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma</title><author>Tanaka, Shogo ; Shinkawa, Hiroji ; Tamori, Akihiro ; Takemura, Shigekazu ; Uchida‐Kobayashi, Sawako ; Amano, Ryosuke ; Kimura, Kenjiro ; Ohira, Go ; Nishio, Kohei ; Tauchi, Jun ; Kinoshita, Masahiko ; Kawada, Norifumi ; Kubo, Shoji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>antiviral agents</topic><topic>Bilirubin</topic><topic>carcinoma</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>hepatocellular</topic><topic>Hepatocellular carcinoma</topic><topic>immunotherapy</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Shogo</creatorcontrib><creatorcontrib>Shinkawa, Hiroji</creatorcontrib><creatorcontrib>Tamori, Akihiro</creatorcontrib><creatorcontrib>Takemura, Shigekazu</creatorcontrib><creatorcontrib>Uchida‐Kobayashi, Sawako</creatorcontrib><creatorcontrib>Amano, Ryosuke</creatorcontrib><creatorcontrib>Kimura, Kenjiro</creatorcontrib><creatorcontrib>Ohira, Go</creatorcontrib><creatorcontrib>Nishio, Kohei</creatorcontrib><creatorcontrib>Tauchi, Jun</creatorcontrib><creatorcontrib>Kinoshita, Masahiko</creatorcontrib><creatorcontrib>Kawada, Norifumi</creatorcontrib><creatorcontrib>Kubo, Shoji</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Shogo</au><au>Shinkawa, Hiroji</au><au>Tamori, Akihiro</au><au>Takemura, Shigekazu</au><au>Uchida‐Kobayashi, Sawako</au><au>Amano, Ryosuke</au><au>Kimura, Kenjiro</au><au>Ohira, Go</au><au>Nishio, Kohei</au><au>Tauchi, Jun</au><au>Kinoshita, Masahiko</au><au>Kawada, Norifumi</au><au>Kubo, Shoji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma</atitle><jtitle>Hepatology research</jtitle><date>2021-11</date><risdate>2021</risdate><volume>51</volume><issue>11</issue><spage>1102</spage><epage>1114</epage><pages>1102-1114</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
We investigated effects of direct‐acting antiviral (DAA)–induced sustained virological response (SVR) after liver resection in patients with hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) for postoperative recurrence and survival.
Methods
Surgical outcomes in 18 patients with postoperative DAA‐induced SVR (HCC‐DAA group) were compared with those in 23 patients with preoperative DAA‐induced SVR (DAA‐HCC group) and those in 10 patients who did not receive DAA therapy (control group). Patients who received DAA therapy >1 year after surgery and those with recurrence <1 year after surgery were excluded.
Results
Serum concentrations of aminotransferases improved 1 year after surgery in both the HCC‐DAA and DAA‐HCC groups. The number of HCC‐DAA patients with albumin‐bilirubin (ALBI) grade 1 increased from 11 to 15. The disease‐free survival rate did not differ between HCC‐DAA group (3 years, 60%) and the other two groups (DAA‐HCC group, 92% and control group, 60%). The 3‐year overall survival rates were better in the DAA‐HCC group (84%) and HCC‐DAA group (100%) than in the control group (46%; all ps < 0.05 according to Holm's test). Multivariable analysis revealed that tumor stage was an independent risk factor for postoperative recurrence, and ALBI grade at 1 year after surgery was predictive of postoperative survival, but DAA‐induced SVR was neither.
Conclusions
Although postoperative DAA‐induced SVR itself may not suppress postoperative recurrence, improvement in liver function as a result of DAA administration after surgery may prolong postoperative survival.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/hepr.13709</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2021-11, Vol.51 (11), p.1102-1114 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2569384562 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | antiviral agents Bilirubin carcinoma Hepatitis Hepatitis C hepatocellular Hepatocellular carcinoma immunotherapy Liver Liver cancer Patients Risk factors Surgery Surgical outcomes Survival Tumors |
| title | Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A58%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20direct%E2%80%90acting%20antiviral%20treatment%20after%20liver%20resection%20in%20patients%20with%20hepatitis%20C%20virus%E2%80%90related%20hepatocellular%20carcinoma&rft.jtitle=Hepatology%20research&rft.au=Tanaka,%20Shogo&rft.date=2021-11&rft.volume=51&rft.issue=11&rft.spage=1102&rft.epage=1114&rft.pages=1102-1114&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13709&rft_dat=%3Cproquest_cross%3E2590169295%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3589-1240a191bbb90eda3d99eb13331630834e133f1bbd3332a35858321f5e12961b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2590169295&rft_id=info:pmid/&rfr_iscdi=true |